Protagonist Therapeutics

05/26/2026

Led by our Chief Medical Officer and Stanford alum, Arturo Molina, Protagonist Therapeutics had the opportunity to host Stanford Medicine PhD and post-doctoral students at our office to learn about careers in biotech and pharma.

Our team had a wonderful time connecting with the next generation of scientists who aspire to be at the forefront of innovative medicine. Thank you to all who attended and made this event a success!

05/15/2026

Thank you to all who joined us at TIDES USA 2026 in Boston!

It was an honor to have our Executive Vice President and Chief Discovery Officer Ashok Bhandari, PhD, give a keynote presentation on Protagonist's story of revolutionizing peptide drug discovery through our unique multi-component technology platform. He also presented on what's next for our company as we advance a next-generation oral IL-17 antagonist peptide for inflammatory diseases.

Discover more about how we're addressing unmet needs with peptide technology: https://www.protagonist-inc.com/areas-of-focus

05/14/2026

Our President and CEO Dinesh V. Patel joined CNBC’s Fast Money to discuss the recent approval of ICOTYDE, our company's licensing deals, ongoing clinical trials, and more.

Watch it here:

Dinesh Patel, Protagonist Therapeutics CEO, joins 'Fast Money' to talk earnings, commercialization, and partnerships.

04/28/2026

Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV).

Protagonist becomes eligible to receive up to $400 million in opt-out payments, consisting of $200 million payable upon the opt-out election and a further $200 million payable upon FDA approval of rusfertide for the treatment of adults with PV. In addition, U.S. approval of rusfertide would trigger a $75 million milestone payment, bringing total potential cash payable in connection with the opt-out election and U.S. approval to $475 million.

Read more: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-exercises-rusfertide-u.s.-opt-out-right-under-takeda-coll-1161793

04/17/2026

"The first approval is just the beginning." - President and CEO Dinesh V. Patel in an interview with Biotechtv this past February.

From Protagonist's pioneering work in peptide therapeutics over 13 years ago to our expanding development programs in obesity and I&I today, our team is driven to tackling unmet medical needs with the power of peptide drug discovery and development.

Watch the full interview to learn more about our peptide technology platform and what's on the horizon for our company:

CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-17, a hepcidin mimetic, and obesity medicines.Protagonist Feb 19

04/07/2026

For patients living with polycythemia vera, fatigue is much more than just feeling tired.

In an interview with Cure Today, one patient describes how PV-related fatigue combined with fatigue from phlebotomies used to manage her disease takes a toll on her quality of life.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

03/20/2026

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.

03/18/2026

Today, we're thrilled to announce that the U.S. FDA has approved ICOTYDE™ (icotrokinra), an innovative new first-line systemic treatment oral option for plaque psoriasis.

ICOTYDE is the first and only targeted oral peptide that precisely blocks the interleukin-23 (IL-23) receptor.

From discovery through development, our teams have worked tirelessly for 13 years to advance ICOTYDE from an idea to an approval, and expect it to make a real difference for patients and the medical community.

This landmark approval validates the power of our science, our platform, and the amazing dedication of team Protagonist.

Thank you to our incredible employees, Johnson & Johnson, the clinical investigators, and the patients who made this achievement possible.

Read the full announcement here: https://bit.ly/4sckfLP

03/08/2026

Happy International Women's Day! This year's theme, Give to Gain, encourages a mindset of generosity and collaboration in support of women's advancement to create a better future for all.

We are proud of our Protagonist team for exemplifying this sentiment and celebrate their successes and contributions as we pursue our mission to improve patient lives.

03/02/2026

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV).

Read more details in our latest press release: https://feeds.issuerdirect.com/news-release.html?newsid=6757000672131462&symbol=PTGX